Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegr…
Biotechnology
US, Cambridge [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Scholar Rock Holding Corporation's gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2019 | -3.1500 | -1.886 | 0 | 18 | -49 | -157 | -49 | -10 | -51 | -10 | 14 | 26 |
| 2020 | -1.8000 | -2.572 | 20 | 18 | -49 | -214 | -53 | -11 | -108 | -11 | 20 | 26 |
| 2021 | -2.7700 | -3.449 | 15 | 19 | -84 | -287 | -85 | -11 | -160 | -11 | 28 | 27 |
| 2022 | -3.5900 | -2.165 | 18 | 33 | -131 | -180 | -127 | -19 | -138 | -19 | 40 | 48 |
| 2023 | -2.2100 | -1.899 | 33 | 0 | -131 | -158 | -131 | 0 | -144 | 0 | 43 | 0 |
| 2024 | -1.9900 | -2.429 | 0 | 0 | -165 | -202 | -168 | 0 | -174 | 0 | 49 | 0 |
| 2025 | - | -2.223 | - | 26 | - | -145 | - | -15 | - | -15 | - | 38 |
| 2026 | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F71/td> | - | 2.F71 | - | 2.F71 |
| 2027 | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F81/td> | - | 1.F81 | - | 1.F81 |
| 2028 | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F91/td> | - | 0.F91 | - | 0.F91 |